ANKE BIO(SZ:300009)2022-12-08 05:28Group 1: Company Development Strategy - The company aims to strengthen and expand its operations with a focus on biopharmaceutical technology, supported by chemical and traditional Chinese medicine as two wings of development [2][3] - Currently, the company has three recombinant drugs expressed in prokaryotic cells and is developing an antibody drug in mammalian cells, with plans to establish an industrialization platform for mammalian expression [2][3] Group 2: Acquisition Strategy - The acquisition of Beijing Huimin Traditional Chinese Medicine Children's Hospital aligns with the company's health service strategy and aims to accumulate experience in the medical service sector [3][4] - The company has invested in a 55% stake in the hospital, viewing it as a unique opportunity due to its specialized focus on traditional Chinese medicine for children [3][4] Group 3: Future Directions and Competitiveness - The hospital aims to develop a profitable model that can be replicated in other cities, focusing on preventive care in line with national medical development plans [4] - The company's core competitive advantages include a strong emphasis on research and development, a stable workforce, and a dedicated academic promotion team [4]